(Suzhou China, September 25, 2023) – Alephoson proudly announces its participation in the prestigious China BioMed Innovation and Investment Conference 2023 (CBIIC), where the company showcased its innovative breakthrough in ophthalmology patient care. Dr. Benjamin Lee, CEO of Alephoson, represented the company and delivered a compelling presentation titled “Innovative Breakthrough in Ophthalmology Patient Care: Novel Aflibercept-CPP Eye-Drop Treatment in Patients with Diabetic Retinopathy (DR) and Retinal Vein Occlusion (RVO).”

CBIIC is renowned for bringing together industry leaders, investors, and innovators from the biopharmaceutical sector to discuss the latest advancements and investment opportunities.

During his presentation, Dr. Benjamin Lee highlighted the innovative approach and remarkable results achieved with Alephoson’s aflibercept-CPP eye drops in patients suffering from DR and RVO. The treatment has shown promising outcomes in improving vision and retinal health, providing new hope for patients facing these conditions.

Alephoson Biopharmaceuticals Ltd. remains committed to driving advancements in ophthalmology treatments with the goal of improving the quality of life for patients worldwide.